research centers


Search results: Found 10

Listing 1 - 10 of 10
Sort by

Article
HER-2/neu overexpression in breast cancer

Authors: Nabeel W. Rasheed --- Rana S. Aziz
Journal: Journal of the Faculty of Medicine مجلة كلية الطب ISSN: 00419419 Year: 2010 Volume: 52 Issue: 3 Pages: 290-294
Publisher: Baghdad University جامعة بغداد

Loading...
Loading...
Abstract

Background: In breast carcinoma, amplification &/or over-expression of HER-2/neu has been associated with a group of unfavorable prognostic factors. The Food & Drug Administration Agency approved Trastuzumab (Herceptin) for the therapy of metastatic breast cancer but only in patients with amplification &/or over-expression of this gene. Because of these advances, evaluation of HER-2/neu status in breast cancer specimens is of vital importance.
Patients and methods: thirty eight females with breast carcinoma were included in this study. All histologic sections were stained routinely with the hematoxylin and eosin stains and immunohistochemically for HER2/neu. All cancers were graded and subcategorized into ductal and lobular carcinomas, with or without an insitu component, and with or without Paget disease. The assessment of HER-2/neu over-expression was quantitated.
Results: Of the twenty four cases of infiltrative duct carcinoma (IDC), HER-2/neu staining was positive in ten (41.7%) cases. None of the fourteen cases of infiltrative lobular carcinoma (ILC) showed a positive reaction. Statistical analysis revealed no significant differences in respect to HER2/neu expression between IDC with and without ductal carcinoma in situ (DCI). All cases of IDC with overlying Paget disease (5 cases; 13.2%) were positive for the stain. All grade I cancers were negative for HER-2/neu over-expression, in contradistinction to a positive staining in 41.7% grade II tumors and 62.5% grade III tumors.
Conclusion: there is significant correlation between HER2/neu overexpression and cancer histopathological type. The presence or absence of an in situ component had no effect on the marker overexpression. Significant correlation was observed between HER-2/neu overexpression and higher histological grades of IDC. No correlation was found between the positivity of the marker and axillary lymph node status. Similarly, no association was found with the other variables except the size of tumor. It is recommended that HER-2/neu assessment to be included as a routine test in the screening program of all breast cancer Iraqi patients.


Article
Immunohistochemical evaluation of Her-2/neu overexpression in breast carcinoma in Mosul

Authors: Nadwa S. Mustafa ندوة صبحي مصطفى --- Mohammed S. Saeed محمد سامي سعيد --- Shuaib H. Saleem شعيب هاشم سليم
Journal: Annals of the College of Medicine Mosul مجلة طب الموصل ISSN: 00271446 23096217 Year: 2008 Volume: 34 Issue: 2 Pages: 87-92
Publisher: Mosul University جامعة الموصل

Loading...
Loading...
Abstract

Objective: To evaluate the overexpression of Her-2/neu in patients with breast cancer in Mosul (both invasive and intraductal) against other prognostic parameters of mammary carcinomas, such as histological type, grade, tumor size, patient age and number of lymph nodes involved.
Methods: This is a retrospective study conducted in the Pathology laboratory of Al-Jamhoori Teaching Hospital and at private laboratories. A total of 36 breast cancer cases and 4 benign cases were diagnosed and collected in a period spanning from April 2006 to April 2007. We used Immunohistochemistry to evaluate the overexpression of Her-2/neu against the age, tumor size, type and grade and the axillary lymph node status.
Results: The mean age of all cases was 47.5 years ranging from 28 to 72 years. Regarding the age, Her-2 positivity was shown in 2 peaks (4th and 7th decades), while Her-2 negativity was found in older age group (p=0.004). Overall Her-2 overexpression was in 37% of the cases; it was overexpressed in 34.5% of invasive ductal carcinoma, in 100% of medullary carcinoma and in 100% of ductal carcinoma in situ. Whereas no expression (0.0%) was seen in 3 cases of invasive lobular carcinoma and one case of colloid carcinoma. Her-2 positivity was associated with large size (T2 and T3) rather than small size tumors (p=0.015). There was a correlation between Her-2 positivity and high grade tumor [G3 in 69.2% of the positive cases (p=0.045)]. Her-2 positivity was associated with axillary lymph node metastasis in 84.6% of cases, but not reaching a statistical significance. The benign lesions included in this study (two fibroadenoma, one fibrocystic disease and one duct ectasia) all showed negativity for Her-2 stain.
Conclusion: Her-2 overexpression was found in 37% of breast cancer in Mosul. Regarding age incidence Her-2 overexpression was noted at 2 peaks 3rd and 6th decades. Large size and high grade breast carcinomas were associated with high percentage of Her-2 positivity, and the majority of Her-2 positive cases had axillary lymph node metastases.
Key words: Breast carcinoma, Her-2/neu expression

الهدف: تقييم شدة إظهار مستلمات Her-2/neu لمريضات سرطان الثدي في مدينة الموصل و لكلا نوعيه(المقيم والمنتشر). كذلك مقارنته مع عناصر أخرى للعوامل الانذارية للمرض مثل نوع السرطان النسيجي, درجة تقدم المرض, حجم المرض, عمر المريضة ووجود انتشار المرض إلى العقد اللمفاوية.تصميم الدراسة: دراسة رجعية لحالات سرطان الثدي عند النساء في مدينة الموصل.طريقة إجراء البحث: تمت الدراسة في مختبر المستشفى الجمهوري التعليمي /قسم النسيج المرضي مع جمع عينات من المختبرات الأهلية فكان العدد الكلي للعينات ست وثلاثون حالة لسرطان الثدي مع جمع أربع عينات من آفات الثدي الحميدة للفترة مابين نيسان 2006 إلى نيسان 2007. تم استخدام صبغة خاصة (صبغات مناعية نسيجية) لإبراز درجة إظهار مستلمات Her-2/neu ومقارنتها مع العوامل الانذارية الأخرى.النتائج: كان معدل أعمار الحالات المدروسة 47.5 سنة (تتراوح مابين 28 إلى 72 سنة). اغلب الحالات التي أظهرت ايجابية لمستلمات Her-2/neu كانت في العقدين (الثالث و السادس). إما أكثر الحالات التي أظهرت سلبية لمستلمات Her-2/neu ففي الفئات العمرية الأكبر. كانت نسبة ايجابية إظهار مستلمات Her-2/neu هو 37% من الحالات. 34.5% من الحالات الإيجابية هي من نوع سرطان الثدي القنوي الانتشاري, كما كانت شدة الظهار للمستلمات أكثر مع الإحجام الأكبر للسرطان ومع الدرجات المتقدمة للسرطان. 84.6% من الحالات التي أظهرت ايجابية لمستلمات Her-2/neu كانت منتشرة للعقد اللمفاوية. الاستنتاج: نسبة ايجابية إظهار مستلمات لسرطان الثدي في مدينة الموصل كانت 37%. وخاصة في العقدين الثالث والسادس وفي الأورام الأكبر حجما وفي الدرجات المتقدمة للسرطانات. معظم الحالات الإيجابية كانت منتشرة للعقد اللمفاوية.


Article
Immunohistochemical study of HER-2 /neu in invasive ductal carcinoma of breast
.

Authors: Maather Baqer Hussein Al-Harmooshy مأثر باقر حسين --- Shoroq Mohammad Abbas Al-Temimi شروق محمد عباس
Journal: Al-Qadisiyah Medical Journal مجلة القادسية الطبية ISSN: 18170153 Year: 2011 Volume: 7 Issue: 11 Pages: 95-105
Publisher: Al-Qadisiyah University جامعة القادسية

Loading...
Loading...
Abstract

Abstract
This study was conducted to estimate the overexpression of HER-2eu protein in human breast carcinoma in comparison to benign breast lesions and to show its possible correlation to the pathological parameters (histological type, grade and age). We evaluated the available tissue blocks of 50 patients with breast lesions (38 with invasive ductal carcinoma & 5 cases with fibroadenoma , 5 cases with fibrocystic disease & 2 cases with normal tissue) who had referred to Al-diwaniya Hospital between January 2007 and December 2010 All cases were female.
The mean age of the patients was 55 years (range, 33 to 77 years). The tumors were grade 1, 2, and 3 in 6 (15.7%), 19 (50%), and 13 (34.3%) cases, respectively. From 38 cases of IDC , A total of 12 (31.5%) patients were positive for overexpression of HER- 2/neu oncogene and From 12 cases of non malignant cases all of them were negative for overexpression of HER- 2/neu oncogene . The positive cases was with strong positive 3+ in 21.2% and in score 1 and 2 in 5.2% . High histologic grades of the breast IDC were associated with increased expression of HER-2/neu. There were 2 cases of HER-2/neu-positive (16.6%) with a grade 1 tumor, 4 (33.4%) with grade 2, and (50%) with grade 3 (P = .002 .There was a significant difference in HER-2/neu overexpression with the invasive ductal carcinoma and but no correlation was detected between HER-2/neu overexpression and the patient’s age.
Aim of the Study: This study was conducted to estimate the overexpression of HER-2eu protein in human breast carcinoma in comparison to benign breast lesions and to show its possible correlation to the pathological parameters ( grade and age) .

يهدف البحث إلى دراسة التعبير المناعي النسيجي الكيميائي لجين أل HER-2/neu كمؤشر للتغيرات الجينية الطارئة في ألخلايا السرطانية لأورام الثدي ومقارنته في النسيج الحميد ولمعرفة ترابط هذا التغير مع ثوابت أخرى مثل عمر المريض و درجة تمايز الورم. تمت دراسة 50 عينة من عقدة الثدي في مختبرات مستشفى الديوانية التعليمي للفترة منذ بداية كانون الثاني 2007 وحتى كانون الاول 2010 , تم جمع 38 عينة من مرضى مصابين بسرطان الثدي و12 عينة من ورم الثدي الحميد , تراوحت أعمارهم بين 33 و 70 سنه مع معدل عمر 55 سنه ،وقد قورنت المجموعتان مع بعض. أظهرت الدراسة المناعية النسيجية أن تعبير أل- HER-2/neu كان موجبا في 31.5% من سرطان الثدي, ولا يوجد تعبير في عينات الورم الحميد .كان تعبير ال- HER-2/neu أكثر في المرضى ضمن مجموعة العمر الأكبر من خمسين عاما , في الأورام ذات التمايز الضعيف(الدرجة الثالثة ) عنه في الأورام ذات التمايز القوي والمتوسط (الدرجة الأولى والثانية ).مع عدم وجود ترابط بين التعبير المناعي النسيجي ا ل- HER-2/neu مع العمر (قيمة ألفا > 0.05) كما انه توجد علاقة واضحة لتعبير ا ل- HER-2/neu مع درجة التمايز ( قيمة ألفا < 0.05). مما يدل على ان جين أل-HER-2/neu يلعب دور أساسي في تقييم حالة سرطان الثدي المستقبلية وانتشاره وتحديد أهمية الاستجابة للعلاج .


Article
Correlation of HER-2/neu Oncogene Expression And Grades of Transitional Cell Carcinoma of Bladder

Author: Dr. Maather Baqer Hussein Al-Harmooshy / Msc general pathology
Journal: KUFA MEDICAL JOURNAL مجلة الكوفة الطبية ISSN: 1993517X Year: 2011 Volume: 14 Issue: 2 Pages: 90-97
Publisher: University of Kufa جامعة الكوفة

Loading...
Loading...
Abstract

This study was conducted to estimate the overexpression of HER-2eu oncoprotein in human transitional cell carcinoma of bladder and to show its possible correlation to the specific pathological parameters like grade of tumor. We evaluated the available tissue blocks of 50 patients with transitional cell carcinoma who had referred to Al-diwaniya Hospital/ department of pathology in a period between January 2006 and December 2010, 32 cases were male and 18 cases were female. The mean age of the patients was 57.5 years (range from 33 to 82 years). The cases were classified according to the grading system into grade I, II, and III in 9, 24 and 17 cases respectively. From 50 cases of TCC, A total of 19 (38%) patients were positive for overexpression of HER- 2/neu oncogene, 12 (63.2%) cases of them with predominant membranous and cytoplasmic staining and 7 (36.8%) cases of them with cytoplasmic staining , there was no pure membranous staining. High histological grades of the TCC were associated with increased expression of HER-2/neu, There was 1 (11%) case of HER-2/neu-positive with a grade I tumor, 7 (29%) with grade II, and 11 (63.7%) with grade III (P =.002) There was a significant relationship in HER-2/neu over expression with high grade of TCC. Aim of the study:The aim of this study was to evaluate the relationship between HER-2/neu oncogene expression and grade of transitional cell carcinoma (TCC) of the bladder.

البحث عن التعبير المناعي النسيجي الكيميائي لجين أل HER-2/neu في خلايا سرطان المثانة الانتقالي ومعرفة ترابط هذا التغير مع درجة تمايز الورم. تمت دراسة 50 عينة من سرطان المثانة الانتقالي في مختبرات مستشفى الديوانية التعليمي للفترة منذ بداية كانون الثاني 2006 وحتى كانون الأول 2010, تراوحت أعمارهم بين 33 و82 سنه مع معدل عمر 57.5 سنه،32 ذكر و18 أنثى, صنفت العينات حسب درجة التمايز إلى 9 عينات من الدرجة الأولى 24 عينة من الدرجة الثانية و17 عينة من الدرجة الثالثة على التوالي. أظهرت الدراسة المناعية النسيجية أن تعبير أل- HER-2/neu كان موجبا في 19 عينة (38%) من سرطان المثانة الانتقالي, وكان أكثر في العينات ذات التمايز الضعيف (الدرجة الثالثة) عنه في العينات ذات التمايز القوي والمتوسط (الدرجة الأولى والثانية). كما انه توجد علاقة واضحة لتعبير ا لHER-2/neu مع درجة التمايز (قيمة ألفا < 0.05). مما يدل على أن جين أل-HER-2/neu يلعب دور أساسي في تقييم حالة سرطان المثانة الانتقالي المستقبلية وانتشاره وتحديد أهمية الاستجابة للعلاج.


Article
Correlation and frequency of HER-2/neu Status With Estrogen and Progesterone Receptors in Breast Carcinomas

Authors: Nazar J. Metib --- Haider Jebur Kehiosh --- Sabah K. Hamzah
Journal: Karbala Journal of Medicine مجلة كربلاء الطبية ISSN: 19905483 Year: 2016 Volume: 9 Issue: 2 Pages: 2588-2599
Publisher: Kerbala University جامعة كربلاء

Loading...
Loading...
Abstract

background: Breast cancer is the most common malignant tumor in Iraqi females accounting for a third of registered female cancers. Prognosis and management are influenced by the classic variables such as histologic type and grade, in addition to tumor size, lymph node status, status of hormone receptors of the tumor and HER-2/neu status. HER-2/ neu, also known as c-erb B-2 (HER-2), a proto-oncogene located on chromosome 17, is amplified and/or the protein (HER-2) overexpressed in 15% to 25% of invasive breast carcinomas and is associated with a worse clinical outcome. The interrelationship of ER(estrogen receptor), PR (progesterone receptor), and HER-2 expression in invasive breast cancer has come to have an important role in the management of breast cancer. It has been shown that patients with breast carcinoma overexpressing HER-2 do not respond to tamoxifen therapy.Objectives: To evaluate HER-2/neu overexpression in breast cancer by immunohistochemical study and to study the correlation between HER-2/neu status and expression of ER and PR receptors and other clinicopathological features in invasive breast carcinoma.Patients and methods: Immunohistochemical analyses were performed successfully for ER, PR, HER-2/neu by streptavidin biotin indirect immunohistochemical methods using monoclonal antibodies for 41 specimens of formalin-fixed, paraffin embedded breast cancer tissue.Results:. There was a significant difference in HER-2/neu overexpression between invasive ductal carcinoma of NOS (Not Otherwise Specified) type from other histopathologic types (lobular, and specified type ductal carcinoma). No significant correlation was observed between HER-2/neu overexpression and higher histological grades of invasive ductal carcinoma. The expression of ER or PR was decreased significantly in HER-2/neu positive tumors in comparison with HER-2 negative tumors .Only 7.3 % of all cases (3/41) were negative for estrogen , progesterone receptors (ER/PR) and HER2/neu oncoprotein (Triple negative breast cancers).The two cases of lobular carcinoma and the three cases of the special-type carcinomas were negative for HER-2/neu. Conclusions: HER-2/neu protein was expressed more in ductal carcinoma ( NOS type ) than in lobular or in carcinoma of special type and frequently detected in higher-grade invasive ductal carcinoma tumors.The expression of ER or PR was decreased significantly in HER-2/neu positive tumors. HER-2/neu positivity was not correlated with other clinico-pathological parameters like age of the patient, menopausal state, primary tumor size and axillary lymph nodes status.

Keywords

Breast carcinomas --- HER-2/neu --- ER --- PR


Article
Over expression of HER2/ neu oncogene in breast cancer in Diwanya city by immunohistochemistry

Author: Aws Rasool Hussein
Journal: KUFA MEDICAL JOURNAL مجلة الكوفة الطبية ISSN: 1993517X Year: 2012 Volume: 15 Issue: 2 Pages: 16-23
Publisher: University of Kufa جامعة الكوفة

Loading...
Loading...
Abstract

Abstract :- This study was conducted to estimate the over expression of HER-2eu protein in human breast carcinoma and to show its possible correlation to the pathological parameters (histological type, grade and age). We evaluated the available tissue blocks of 49 patients with breast lesions who had collected from private laboratory between January 2007 and October 2009. All cases were female. The mean age of the patients was 46.5 years (range, 20 to 73 years old). 38(77.5%) cases were of infiltrative ductal carcinoma and 11(22.5%) cases were of infiltrative lobular carcinoma , The tumors were grade I, II, and III in 3(7.9%),24(63.2%),and11(28.9 (cases respectively. From 49 cases, A total of 16 (32.25%) cases were positive for overexpression of HER- 2/neu oncogene , all the positive cases was with IDC , the intermediate histological grades of the breast IDC were associated with highest expression of HER-2/neu. There were 14 cases of HER-2/neu-positive (58.4%) with a grade II tumor, 2 (37.5%) with grade III .There was a significant relation in HER-2/neu overexpression with the invasive ductal carcinoma and grades of tumor but no correlation was detected between HER-2/neu overexpression and the patient’s age.Aim of the Study: This study was conducted to estimate the overexpression of HER-2eu protein in human breast carcinoma and to show its possible correlation to the pathological parameters (types , grade and age).

ألخلاصه:-يهدف البحث إلى دراسة التعبير المناعي النسيجي الكيميائي لجين أل HER-2/neu كمؤشر للتغيرات الجينية الطارئة في ألخلايا السرطانية لأورام ألثدي ولمعرفة ترابط هذا التغير مع ثوابت أخرى مثل عمر المريض و درجة تمايز الورم ونوعه. تمت دراسة 49 عينة من عقدة الثدي في مختبرات خاصة للفترة منذ بداية كانون الثاني 2008 وحتى تشرين الأول 2009 , تراوحت أعمارهم بي20 و 73 سنه مع معدل عمر 46,5 سنه. أظهرت الدراسة المناعية النسيجية أن تعبير أل- HER-2/neu كان موجبا في32,25% من سرطان الثدي حيث كان تعبير ال- HER-2/neu أكثر في المرضى ضمن مجموعة العمر الاكبر من خمسين عاما , وفي الأورام العقدية عنه في الأورام الفصية و في ألأورام ذات التمايز المتوسط (الدرجة الثانية ). مع عدم وجود ترابط بين ألتعبير المناعي النسيجي ا ل- HER-2/neu مع العمر (قيمة ألفا > 0.05) كما انه توجد علاقة واضحة لتعبير ا ل- HER-2/neu مع نوع الورم و درجة التمايز (قيمة ألفا < 0.05). مما يدل على أن جين أل-HER-2/neu يلعب دور أساسي في تقييم حالة سرطان الثدي المستقبلية وانتشاره.


Article
The Study of HER-2/neu, ER/PR Expression Using Immunohistochemistry (IHC) in the Iraqi Breast Cancer

Loading...
Loading...
Abstract

Background: Breast cancer is the most common cancer in woman that originates from the uncontrolled growth of abnormal breast cells. According to the Iraq Cancer Registry 2009, breast cancer ranks as the first between the ten common cancers in Iraq and there is a wide tendency to increase the rate of breast cancer in earlier age group. Estimation of estrogen (ER) and progesterone (PR) receptors status as well as human epidermal growth factor receptor 2(Her-2/neu) serve as specific guidance to select the patients whose benefit from endocrine therapy and provide prognostic information. The study aimed to assess the expression of ER/PR hormone receptor and Her-2/neu in breast cancer patients and correlation with various Clinicopathological aspects as a predictive biomarker.Method: The current study was performed from the period between Jan 2015-Feb 2015 in Department of Oncology that referred to Baghdad Teaching Hospital in the Medical City. Routine staining hematoxylin and eosin (H&E) for histopathological examination and immunohistochemistry (IHC) test for ER, PR and Her-2/neu expression was conducted in all cases.Results: This study includes total 30 cases of breast cancer. The age of patients were between 29-65 years with 47± 9.8 (mean ±SD). Majority of tumors are invasive ductal carcinomas represented 23(76.7%).There are significant differences between different scores were observed in IHC test for Her-2/neu status and showed 8(26.7%) out of 30 cases were positive expression.The ER and PR expression status was strongly associated and demonstrated in 21(70%) of cases.The most commune subgroup was Her-2/neu+, ER/PR+ seen in 10(33.3%) out of 30 breast cancer patients. Conclusion: HER-2/neu is positively expressed in about 26.7% of breast cancer cases.The study of ER, PR status showed higher rates of positive expression70% and was strongly associated. Using IHC examination the Her-2/neu+, ER/PR+ subgroup indicates the most common subtype 10 (33.3%) compared to other tumor subtypes in breast cancer.

Keywords

Breast cancer --- ER/PR --- Her-2/neu --- IHC


Article
Breast Cancer in Kirkuk City, Hormone Receptors Status (Estrogen and Progesterone) and Her-2/Neu and Their Correlation with Other Pathologic Prognostic Variables

Author: Mahmoud Mohammed Mahmoud محمود محمد محمود
Journal: Diyala Journal of Medicine مجلة ديالى الطبية ISSN: 97642219 Year: 2014 Volume: 6 Issue: 1 Pages: 1-14
Publisher: Diyala University جامعة ديالى

Loading...
Loading...
Abstract

Background: Breast cancer shows different clinic- pathological features according to geographic and ethnic groups variation. The ER, PR and Her-2/neu positive status is an indication that the patient is good candidate for hormonal and immunological therapy.Aim of the study: To measure the frequency of estrogen receptor (ER), progesterone receptor (PR), and Her 2/neu positivity and to study their association with other variables in a breast cancer in Kirkuk city.Material and method: A prospective study of 138 female breast cancers in Kirkuk city from October 2012 to December 2013.Results: The age of the patients ranged from16 to 75 years, with a mean of 47 years, most common age group involved was 41-50 years, majority of our patients were less than 50 years, tumor grade III, tumor size between 2-5cm. ER, PR and Her-2/neu expression was seen in 50.7, 47.8 and 41.3% respectively, a characteristic association also found between hormone receptor and Her-2/neu expression and various clinic-pathological parameters.Conclusion: The hormonal receptor expression appear to be lower and Her-2/neu expression appear to be higher in our population compared to the West and a significant reverse association was found between hormone receptor and Her-2/neu.


Article
Iraqi Breast Cancer: A Review on Patients' Demographic Characteristics and Clinico-Pathological Presentation.

Author: Nada A. S. Alwan ندى العلوان
Journal: Journal of the Faculty of Medicine مجلة كلية الطب ISSN: 00419419 Year: 2010 Volume: 52 Issue: 1 Pages: 105-110
Publisher: Baghdad University جامعة بغداد

Loading...
Loading...
Abstract

Background: Breast Cancer is the commonest type of malignancy in Iraq. The Iraqi Cancer Registry displays an obvious trend for the disease to affect younger women with advanced stages at the time of presentation. This report presents a review on the main demographic characteristics and clinico-pathological parameters in Iraqi patients diagnosed with breast cancer.Patients & Methods: The study was carried out on 721 out of a total of 5044 patients (14.3%) who complained of palpable breast lumps that were diagnosed as cancer. The procedure for tumor nuclear DNA Ploidy assessment was performed by means of Image Cytometry. Immuno-cytochemical and histochemical assays were applied for the determination of Estrogen and Progesterone receptor (ER/PR) contents and Her-2/neu expression of the tumor tissues.Results: Approximately one third of the breast cancer patients were diagnosed in the age period (40-49 years), 71.9% came from urban areas and 75% were married. History of lactation and hormonal therapy was reported in 63.1% and 29% respectively, while positive family history was recorded in 16.2%. Although the lump was detected by the patient herself in 90.6%, yet only 32% sought medical advice within the first month. Accordingly 47% of these patients presented in advanced stages (III and IV).The main histological type was invasive ductal carcinoma; in which pathological changes of grade II and III were observed in 56.6% and 39.9% respectively. Cytophotometric DNA analysis showed that 80.3% of Iraqi mammary carcinomas were aneuploid. ER and PR positive tumor contents were demonstrated in 65.1% and 45.1% of the examined specimens respectively while Her-2/neu over expression was displayed in 46.4%.Conclusions: The aforementioned data justifies increasing efforts for establishing comprehensive breast cancer control programs in our country. Further interventional research studies using molecular biomarkers should be promoted to address the factors contributing to the illustrated aggressive tumor behavioral formsKeywords: Breast Cancer, Iraq, Clinical, Pathological Diagnosis, Aneuploidy, Hormone Receptors, Her-2/neu.


Article
Serum Her-2/Neu a Potential Biomarker in Breast Cancer Patients: Correlation with the Clinico-Pathological Parameters

Author: Manar Abed AL-Kreim Abed Oun*, Hedef Dhafir El-Yassin**, Nada A.Al-Alwan***
Journal: Iraqi Academic Scientific Journal المجلة العراقية للاختصاصات الطبية ISSN: 16088360 Year: 2015 Volume: 14 Issue: 4 Pages: 555-563
Publisher: The Iraqi Borad for Medical Specialization المجلس العراقي للاختصاصات الطبية

Loading...
Loading...
Abstract

ABSTRACT:BACKGROUND: Breast cancer is the most common malignancy in women, and a major cause of mortality and morbidity despite the advances in diagnosis and treatment. There is evidence that changes in HER2 protein expressions are associated with breast cancer progression.OBJECTIVE: To investigate whether measuring this tumour marker in serum of breast cancer patients before and after treatment might also be useful markers in the diagnosis, screening and monitoring the malignant tumour progression and response to therapy. METHODS: Serum samples were obtained from (28) apparently healthy women (Control Group) with a mean age of 40.9 ± 7.6 years and (60) female patients complaining from primary breast cancer (Patients Group) with a mean age of 48.3 ± 8.9 years. They were divided according to their clinical end point into: Pre-Surgical Group, Post-Surgical Group and post- chemotherapy Group. Serum Her-2/nue level was measured using ELISA kits.RESULTS: Level of Her2/neu (3130.4 pg/ml) was significantly higher in after 6 cycles of chemotherapy group than each of control (1400.8 pg/ml), before surgery (1597 pg/ml) and after surgery (1487.4 pg/ml) (P < 0.05). Her2/neu is effective test only after 6 cycle chemotherapy with an accuracy of 95.2%. The best performance for Her2neu was observed at values ≥ 1464 pg/ml (sensitivity = 95% and specificity = 61%). There were significant influences of the studied personal and the pathological characteristics of the tumour upon the biomarker levels where the levels were significantly higher with the increase of tumour pathological stage and in the presence of positive status for Her2neu receptors (P < 0.05).CONCLUSION:In this study there was a statistically significant association between tissue HER-2/neu and serum HER-2 /neu levels in the extracellular domain. It could be concluded that using serum Her-2/neu in patients after six cycles chemotherapy could predict response to therapy..

Listing 1 - 10 of 10
Sort by
Narrow your search

Resource type

article (10)


Language

English (9)

Arabic and English (1)


Year
From To Submit

2016 (2)

2015 (1)

2014 (1)

2012 (1)

2011 (2)

More...